Interest of a sequential multimodal approach for the treatment of newly diagnosed patients with multimetastatic Ewing sarcoma: results of the French prospective CombinaiR3 phase II trial.

Journal and index pages often block iframe embedding. This reader keeps the evidence details in Orthonotes and leaves the source page one click away.

Abstract

[Indexed for MEDLINE] Conflict of interest statement: Competing interests: PB has consulting role (institutional funding) for Recordati and Merck, drugs for trials from Bayer, participation in educational activities organised by Recordati and is Member of the Executive Committee of the SIOPEN (European neuroblastoma research cooperative group), organisation which receives royalties for the sales of dinutuximab beta.